- Home
- INCY vs GMAB Comparison
INCY vs GMAB Comparison
Compare INCY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- GMAB
- Stock Information
- Founded
- INCY 1991
- GMAB 1999
- Country
- INCY United States
- GMAB Denmark
- Employees
- INCY N/A
- GMAB N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- INCY Health Care
- GMAB Health Care
- Exchange
- INCY Nasdaq
- GMAB Nasdaq
- Market Cap
- INCY 17.0B
- GMAB 17.4B
- IPO Year
- INCY 1993
- GMAB N/A
- Fundamental
- Price
- INCY $105.96
- GMAB $30.52
- Analyst Decision
- INCY Buy
- GMAB Strong Buy
- Analyst Count
- INCY 19
- GMAB 6
- Target Price
- INCY $89.19
- GMAB $40.40
- AVG Volume (30 Days)
- INCY 2.9M
- GMAB 2.5M
- Earning Date
- INCY 10-28-2025
- GMAB 11-06-2025
- Dividend Yield
- INCY N/A
- GMAB N/A
- EPS Growth
- INCY 3878.02
- GMAB 132.41
- EPS
- INCY 5.90
- GMAB 25.10
- Revenue
- INCY $4,813,105,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- INCY $19.33
- GMAB $24.92
- Revenue Next Year
- INCY $10.47
- GMAB $15.97
- P/E Ratio
- INCY $18.34
- GMAB $1.21
- Revenue Growth
- INCY 18.09
- GMAB 29.57
- 52 Week Low
- INCY $53.56
- GMAB $17.24
- 52 Week High
- INCY $109.28
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- INCY 73.65
- GMAB 57.82
- Support Level
- INCY $91.16
- GMAB $28.08
- Resistance Level
- INCY $109.28
- GMAB $29.35
- Average True Range (ATR)
- INCY 4.54
- GMAB 0.69
- MACD
- INCY 0.92
- GMAB 0.08
- Stochastic Oscillator
- INCY 86.44
- GMAB 88.89
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.